文献速递慢性肾脏病肾小球疾病

联合治疗成为糖尿病与非糖尿病慢性肾脏病新标准

Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

本综述提出联合治疗正在成为糖尿病和非糖尿病慢性肾脏病的新标准。多种药物针对不同机制,随机数据显示各类药物在糖尿病肾病中具有独立且叠加的获益。SGLT2抑制剂可减少高钾血症和液体潴留,可能提高其他治疗的耐受性和安全性。

要点

  • 联合治疗是糖尿病和非糖尿病CKD的新标准,多种药物机制互补。
  • 随机数据显示各类药物在糖尿病肾病中独立且叠加获益,不受背景治疗影响。
  • SGLT2抑制剂减少高钾血症和液体潴留,可能改善其他治疗的耐受性。

核心结论

  • 联合治疗正在成为糖尿病和非糖尿病慢性肾脏病的新标准。
  • 多种药物针对不同机制,随机数据支持各类药物独立且叠加的获益。

研究设计与样本

  • 本综述总结联合治疗在糖尿病和非糖尿病CKD中的随机证据、安全性考虑和正在进行的试验。

主要发现

  • 2型糖尿病患者中已有RAS阻断、SGLT2抑制剂、非甾体盐皮质激素受体拮抗剂和GLP-1受体激动剂等治疗可降低肾衰竭和心血管事件风险。
  • 随机数据提示各类治疗在糖尿病肾病中提供独立且叠加的获益,不受背景治疗影响。
  • SGLT2抑制剂减少高钾血症和液体潴留,可能提高其他治疗的耐受性和安全性。

临床怎么用

  • 根据患者风险实施联合治疗框架,以优化以患者为中心的护理并减少长期肾衰竭及相关并发症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Combination therapy, involving the use of multiple medications together, is becoming a new standard of care for chronic kidney disease (CKD). For people with CKD, combination therapy offers the promise of preventing kidney failure and reducing the risk of heart problems. This approach is appealing because different drugs target distinct mechanisms involved in CKD progression. For instance, some target immune responses, others reduce kidney inflammation and scarring, while others improve blood pressure within the kidneys. Data from large clinical trials suggest that each treatment works effectively on its own, regardless of other medications people are taking. Combining therapies can also reduce the risk of side effects of individual medications. This review highlights the evidence for combination therapy in CKD, explores how to improve its use, and discusses how future studies may answer remaining questions. ABSTRACT: A range of therapies now exists to reduce the risk of kidney failure and cardiovascular events in people with type 2 diabetes, including renin-angiotensin system blockade, sodium-glucose cotransporter 2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists. With multiple clinical trials underway, it is likely that at least some of these therapies-as well as additional agents such as endothelin receptor antagonists-will further demonstrate kidney-protective effects in people with CKD who do not have diabetes in the near future. For conditions such as IgA nephropathy, several therapies have recently been approved or are being evaluated in late phase trials. Thus combination therapy is emerging as a new standard for diabetic and non-diabetic chronic kidney disease (CKD). This approach is supported by randomized data suggesting that each therapeutic class offers independent and additive benefits in diabetic kidney disease, regardless of background therapy. Notably, the reduction in hyperkalaemia and fluid retention with SGLT2 inhibitors may enhance the tolerability and safety of other treatments. In this review, we present the rationale for combination therapy with evidence-based kidney therapies in diabetic and non-diabetic CKD. We also summarize randomized evidence supporting a multi-medicine approach, address safety considerations, review ongoing trials, and propose frameworks for implementing treatments aligned with patient risk to optimize person-centred care and reduce long-term risks of kidney failure and related complications.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Neuen BL, Yeung EK, Rangaswami J, et al. Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease. Nephrol Dial Transplant. 2025. PMID: 39907542. doi:10.1093/ndt/gfae258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。